治疗性抗凝预先使用对住院COVID-19患者临床结局无保护作用:倾向评分匹配队列研究
该回顾性研究纳入2020年3-5月荷兰6家医院1154例住院COVID-19患者,采用1:3倾向评分匹配分析感染前治疗性抗凝与临床结局的关联。
要点
- 感染前治疗性抗凝未改善住院COVID-19患者总死亡率。
- 预先抗凝与住院时长无显著关联。
- 预先抗凝者肺栓塞风险较低,但需权衡出血风险。
核心结论
- 住院COVID-19患者感染前使用治疗性抗凝与临床结局改善无关。
研究设计与样本
- 回顾性队列研究,纳入2020年3-5月荷兰6家医院1154例住院COVID-19患者,采用1:3倾向评分匹配。
主要发现
- 190例(16%)患者入院前使用治疗性抗凝。
- 倾向评分匹配分析显示预先抗凝与总死亡率无关(风险比1.02,95%CI 0.80-1.30)。
- 预先抗凝者肺栓塞风险较低(风险比0.19,95%CI 0.05-0.80)。
临床怎么用
- 不应仅因COVID-19住院而预期预先治疗性抗凝带来生存获益。
- 对已使用治疗性抗凝者需个体化评估肺栓塞与出血风险。
局限性
- 回顾性设计可能存在残余混杂。
- 仅纳入荷兰6家医院2020年3-5月患者,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The hypercoagulable state observed in COVID-19 could be responsible for morbidity and mortality. In this retrospective study we investigated whether therapeutic anticoagulation prior to infection has a beneficial effect in hospitalized COVID-19 patients. This study included 1154 COVID-19 patients admitted to 6 hospitals in the Netherlands between March and May 2020. We applied 1:3 propensity score matching to evaluate the association between prior therapeutic anticoagulation use and clinical outcome, with in hospital mortality as primary endpoint. In total, 190 (16%) patients used therapeutic anticoagulation prior to admission. In the propensity score matched analyses, we observed no associations between prior use of therapeutic anticoagulation and overall mortality (risk ratio 1.02 [95% confidence interval; 0.80-1.30]) or length of hospital stay (7.0 [4-12] vs. 7.0 [4-12] days, P = .69), although we observed a lower risk of pulmonary embolism (0.19 [0.05-0.80]). This study shows that prior use of therapeutic anticoagulation is not associated with improved clinical outcome in hospitalized COVID-19 patients.
引用
- Spiegelenberg JP, van Gelder MMHJ, Maas ML, et al. Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: A propensity score-matched cohort study. Br J Clin Pharmacol. 2021. PMID: 33899226. doi:10.1111/bcp.14877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。